Here’s a summary of the article, focusing on the key findings regarding faricimab treatment for Retinal Vein Occlusion (RVO):
Key Findings:
* Real-world Effectiveness: A real-world study using the Academy IRIS registry showed faricimab is effective and safe for treating RVO with macular edema.
* Visual Acuity (VA) improvement/Maintenance:
* Treatment-Naïve Eyes: Experienced a median improvement of almost 11 letters in visual acuity.
* Previously Treated Eyes: Vision was maintained overall. More than 80% of both treatment-naïve and previously treated eyes maintained or exceeded their VA.
* Central Subfield Thickness (CST) Reduction: Significant reductions in CST were observed in both treatment-naïve and previously treated eyes at 12 months.
* Treatment-Naïve: Reduction from 367.1 µm to 316.6 µm.
* Previously Treated: Reduction from 323.9 µm to 297.2 µm.
* Treatment Interval Extension: Previously treated patients experienced a treatment interval extension of approximately 10 days compared to their prior interval. Both groups (naïve and previously treated) received fewer injections in the second 6 months of treatment.
* CRVO Cohort Results: Similar positive outcomes were seen in the CRVO subgroup, with vision improvement in naïve eyes and maintenance in previously treated eyes. CST also decreased in both groups.
* Safety: The safety profile was consistent with previous clinical trials, with low rates of endophthalmitis (0.06%) and idiopathic orbital inflammation (0.23%).
In conclusion: The study demonstrates that faricimab is a durable,effective,and safe treatment option for RVO in a real-world setting,potentially allowing for extended treatment intervals.
